• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

非小细胞肺癌患者经FDG-PET/CT扫描记录的骨转移早期完全缓解

Early and Complete Response of Bone Metastases, Documented by FDG-PET/CT Scan, in a Patient With NSCLC.

作者信息

Rossi David, Giordani Paolo, Alessandroni Paolo, Catalano Vincenzo, Casadei Virginia, Baldelli Anna Maria, Fedeli Stefano Luzi, Graziano Francesco, Fiorentini Giammaria

机构信息

Azienda Ospedaliera "Ospedali Riuniti Marche Nord", Presidio "San Salvatore" di Pesaro, Italy.

出版信息

World J Oncol. 2012 Feb;3(1):39-41. doi: 10.4021/wjon441w. Epub 2012 Feb 19.

DOI:10.4021/wjon441w
PMID:29147277
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5649835/
Abstract

In this case report we describe the case of a patient with multiple bone metastases of NSCLC, adenocarcinoma with exon 21 point-mutation of EGFR, treated with gefitinib. After only 3 months, FDG-PET/CT scan showed a complete response of bone metastases and right hylar adenopathy. Implications for need of early use of FDG-PET/CT scan after gefitinib treatment are discussed.

摘要

在本病例报告中，我们描述了一名非小细胞肺癌（NSCLC）多发骨转移患者的病例，该患者为腺癌，伴有表皮生长因子受体（EGFR）第21外显子点突变，接受了吉非替尼治疗。仅3个月后，氟代脱氧葡萄糖正电子发射断层显像/X线计算机体层成像（FDG-PET/CT）扫描显示骨转移和右肺门淋巴结病完全缓解。本文讨论了吉非替尼治疗后早期使用FDG-PET/CT扫描的必要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df43/5649835/fcb60719c56c/wjon-03-039-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df43/5649835/869396c747c0/wjon-03-039-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df43/5649835/fcb60719c56c/wjon-03-039-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df43/5649835/869396c747c0/wjon-03-039-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df43/5649835/fcb60719c56c/wjon-03-039-g002.jpg

相似文献

1
Early and Complete Response of Bone Metastases, Documented by FDG-PET/CT Scan, in a Patient With NSCLC.非小细胞肺癌患者经FDG-PET/CT扫描记录的骨转移早期完全缓解
World J Oncol. 2012 Feb;3(1):39-41. doi: 10.4021/wjon441w. Epub 2012 Feb 19.
2
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
3
EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.表皮生长因子受体（EGFR）突变L747P导致一名中国肺腺癌患者对吉非替尼产生耐药，并加速了肝转移。
Int J Clin Exp Pathol. 2015 Jul 1;8(7):8603-6. eCollection 2015.
4
Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.非小细胞肺癌患者的不一致发现：骨扫描完全正常与正电子发射断层扫描/计算机断层扫描显示广泛骨转移。
Eur J Cardiothorac Surg. 2010 Apr;37(4):792-6. doi: 10.1016/j.ejcts.2009.11.011. Epub 2009 Dec 16.
5
Complete metabolic remission with Gefitinib in a hemodialysis patient with bone metastases from non-small cell lung cancer.吉非替尼使合并骨转移的血液透析非小细胞肺癌患者实现完全代谢缓解。
Anticancer Res. 2014 Jan;34(1):319-22.
6
Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question.表皮生长因子受体（EGFR）突变的晚期非小细胞肺癌中的原发性酪氨酸激酶抑制剂（TKI）耐药性：一个悬而未决的问题。
Tumori. 2015 Jul 24;101(4):e115-7. doi: 10.5301/tj.5000317.
7
Comparison of the diagnostic accuracy of 99 m-Tc-MDP bone scintigraphy and 18 F-FDG PET/CT for the detection of skeletal metastases.99m-Tc-MDP骨闪烁显像与18F-FDG PET/CT检测骨转移瘤的诊断准确性比较
Acta Radiol. 2016 Jan;57(1):58-65. doi: 10.1177/0284185114564438. Epub 2014 Dec 22.
8
Efficacy comparison between (18)F-FDG PET/CT and bone scintigraphy in detecting bony metastases of non-small-cell lung cancer.（18）F-FDG PET/CT与骨闪烁显像在检测非小细胞肺癌骨转移中的效能比较
Lung Cancer. 2009 Sep;65(3):333-8. doi: 10.1016/j.lungcan.2008.12.004. Epub 2009 Jan 13.
9
Utility of [18F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) in the Initial Staging and Response Assessment of Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.[18F]氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（FDG PET/CT）在接受新辅助化疗的局部晚期乳腺癌患者初始分期及疗效评估中的应用价值
Indian J Surg Oncol. 2015 Dec;6(4):330-6. doi: 10.1007/s13193-015-0421-0. Epub 2015 Jul 22.
10
Comparison of 18F-FDG PET/CT scan and 99mTc-MDP bone scintigraphy in detecting bone metastasis in head and neck tumors.18F-FDG PET/CT扫描与99mTc-MDP骨闪烁显像在检测头颈部肿瘤骨转移中的比较
Nucl Med Commun. 2016 Jun;37(6):583-8. doi: 10.1097/MNM.0000000000000479.

本文引用的文献

1
[Evaluation of bone scintigraphy and (18)F-FDG PET/CT in bone metastases of lung cancer patients].
Rev Esp Med Nucl. 2011 Jan-Feb;30(1):2-7. doi: 10.1016/j.remn.2010.10.005. Epub 2011 Jan 3.
2
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.吉非替尼或化疗用于治疗具有突变型 EGFR 的非小细胞肺癌。
N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530.
3
The effectiveness of gefitinib on spinal metastases of lung cancer - report of two cases -.吉非替尼对肺癌脊柱转移的疗效——两例报告——
Asian Spine J. 2008 Dec;2(2):109-13. doi: 10.4184/asj.2008.2.2.109. Epub 2008 Dec 31.
4
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.吉非替尼对比顺铂联合多西他赛用于治疗表皮生长因子受体突变的非小细胞肺癌患者（WJTOG3405）：一项开放标签、随机对照 3 期临床试验。
Lancet Oncol. 2010 Feb;11(2):121-8. doi: 10.1016/S1470-2045(09)70364-X. Epub 2009 Dec 18.
5
Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT.肺癌患者骨转移的检测：99mTc-MDP 平面骨显像、18F-氟化物 PET 或 18F-FDG PET/CT。
Eur J Nucl Med Mol Imaging. 2009 Nov;36(11):1807-12. doi: 10.1007/s00259-009-1181-2. Epub 2009 Jun 6.
6
Predictors of survival in patients with bone metastasis of lung cancer.肺癌骨转移患者生存的预测因素。
Clin Orthop Relat Res. 2008 Mar;466(3):729-36. doi: 10.1007/s11999-007-0051-0. Epub 2008 Jan 3.
7
Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib.吉非替尼治疗的非小细胞肺癌患者骨转移的长期控制
Lung Cancer. 2008 Jun;60(3):452-4. doi: 10.1016/j.lungcan.2007.11.002. Epub 2008 Feb 20.
8
Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.唑来膦酸不能诱导细胞凋亡，但可减缓非小细胞肺癌的肿瘤生长并延长生存期。
Lung Cancer. 2008 Feb;59(2):180-91. doi: 10.1016/j.lungcan.2007.08.026. Epub 2007 Sep 27.
9
EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases.表皮生长因子样配体通过调节成骨细胞中破骨细胞调节因子的表达来刺激破骨细胞生成：对溶骨性骨转移的影响
J Biol Chem. 2007 Sep 14;282(37):26656-26665. doi: 10.1074/jbc.M705064200. Epub 2007 Jul 17.
10
Increasing osteoblastic lesions as a manifestation of a major response to gefitinib.
J Thorac Oncol. 2006 Oct;1(8):859-60.